Sigilon Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021

Rhea-AI Summary

Sigilon Therapeutics (NASDAQ: SGTX) will present an overview of its innovative Shielded Living Therapeutics™ platform at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 3:40 p.m. EST. CEO Rogerio Vivaldi, M.D., will lead the presentation, available via live webcast on the company’s website. Sigilon aims to develop functional cures for chronic diseases like hemophilia and diabetes using engineered human cells protected from immune rejection. A replay of the presentation will be accessible post-event.

CAMBRIDGE, Mass., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that its President and Chief Executive Officer, Rogerio Vivaldi, M.D., will present a corporate overview during the 39th Annual J.P. Morgan Healthcare Conference. The presentation will take place on Thursday, January 14 at 3:40 p.m. EST, in a virtual format.

A live webcast of the presentation will be accessible under “Events and Presentations” in the Investors & Media page of the Company's website at www.sigilon.com. A replay of the webcast will be available following the event on the Sigilon website.

About Sigilon Therapeutics
Sigilon Therapeutics seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform. Sigilon’s product candidates consist of novel human cells engineered to produce the crucial proteins, enzymes or factors needed by patients living with chronic diseases such as hemophilia, diabetes and lysosomal storage disorders. The engineered cells are protected by Sigilon’s Afibromer™ biomaterials matrix, which shields them from immune rejection and fibrosis. Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.

Investor Contacts
Glenn Reicin
Sigilon Therapeutics, Chief Financial Officer
glenn.reicin@sigilon.com
646-696-4344

Jennifer Porcelli
Solebury Trout
jporcelli@soleburytrout.com
646-378-2962

Media Contact
Amy Bonanno
Solebury Trout
abonanno@soleburytrout.com
914-450-0349

FAQ

When is Sigilon Therapeutics' presentation at the J.P. Morgan Healthcare Conference?

Sigilon Therapeutics will present on January 14, 2021, at 3:40 p.m. EST.

Who will present for Sigilon Therapeutics at the conference?

Rogerio Vivaldi, M.D., the President and CEO of Sigilon Therapeutics, will present.

How can I access the webcast of Sigilon Therapeutics' presentation?

The live webcast will be available under 'Events and Presentations' on Sigilon's Investors & Media page.

What is the focus of Sigilon Therapeutics' Shielded Living Therapeutics™ platform?

The platform aims to develop functional cures for chronic diseases using engineered human cells.

What chronic diseases does Sigilon Therapeutics target?

Sigilon Therapeutics focuses on diseases like hemophilia, diabetes, and lysosomal storage disorders.